Drawing for SEQUESSOME TECHNOLOGY

USPTO serial 79115050

SEQUESSOME TECHNOLOGY

Reviewed by CopyMark Law Group

Reg. 4427020Status 709
Filing date
Status date
Registration date
Nov 5, 2013
Examiner
TWOHIG, SHANNON MARIE
Law office
TMO LAW OFFICE 121

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SEQUESSOME TECHNOLOGY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Roberta S. Bren

Roberta S. Bren MUNCY, GEISSLER, OLDS & LOWE, P.C.4000 Legato Road, Suite 310Fairfax, VA 22033UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances for the treatment of pain and inflammation; [ veterinary and sanitary preparations and substances for the treatment of pain and inflammation; chemical preparations for pharmaceutical purposes, namely, for the treatment of pain and inflammation; pharmaceuticals for the treatment of osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; anti-inflammatory drugs; ] medicated creams, medicated dispersions, medicated lotions, medicated ointments, medicated gels [, medicated solutions, medicated sprays, medicated lacquers and pharmaceutical solutions which form a film on the skin for the treatment of pain or inflammation; chemical preparations for pharmaceutical or medical purposes, namely, the treatment of pain and inflammation; pharmaceuticals in the fields of osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal disease and central nervous system diseases, namely, vesicles which physically absorb and remove chemicals; pharmaceutical preparations, namely, topical and parenteral preparations in the form of vesicles; pharmaceutical preparations in the form of vesicles for medical and veterinary purposes; pharmaceutical preparations being chemical membranes and chemical aggregates for medical and veterinary purposes for the treatment of pain and inflammation; pharmaceutical preparations of arachidonic acids for the treatment of pain and inflammation; dispersions for pharmaceuticals for the treatment of pain and inflammation; medicated cosmetic and veterinary preparations, namely, dispersions and dry preparations of liposomal active substance carriers for the treatment of pain and inflammation; cosmeceutical preparations in the nature of medicated cosmetics; pharmaceutical preparations, namely, lipids for topical and parenteral use for the treatment of pain and inflammation; surfactants for medical use dispersed in the form of liquids, creams, gels, lotions, or liquid treatment sprays and lotions, being pharmaceutical preparations for the treatment of or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque-type psoriasis, seborrhoeic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea, hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, Alzheimer's disease, gout, macular degeneration, fungal disease and disorders related to fatty acid deficiencies ]SECTION 71 - CANCELLED—
010[ Medical devices in the nature of a carrier with nanostructures which cross through the skin allowing subcutaneous absorption for the treatment of pain; ] molecular filtering devices for medical use, namely, a liquid, gel or cream preparation as a drug delivery device which filters through or migrates into the skin and has a physical therapeutic effect; medical [ and veterinary ] devices, namely, a medical device in which vesicles act as a drug delivery device in the nature of non-pharmaceutical nanostructures that migrate through the skin and which contribute to the lubricating properties of synovial fluid [ ; medical instruments and devices for the administration of skin disease therapy and pain therapy and prophylaxis preparations and substances ]SECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 19, 2025INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Apr 1, 2025INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Apr 1, 2025INPCINVALIDATION PROCESSED—
Jan 18, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
May 17, 2024C71TCANCELLED SECTION 71—
Nov 5, 2022REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Jan 7, 2022RNWLINTERNATIONAL REGISTRATION RENEWED—
Jan 7, 2020NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Jan 7, 2020C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Jan 3, 2020NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 9, 2019APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 5, 2019ES75TEAS SECTION 71 & 15 RECEIVED—
Aug 9, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 5, 2018REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Mar 14, 2016ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 14, 2016REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 28, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 7, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 7, 2014FIMPFINAL DISPOSITION PROCESSED—
Feb 5, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Nov 5, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 20, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 20, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 31, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 17, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 17, 2013ALIEASSIGNED TO LIE—
Jul 17, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 15, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 15, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 15, 2013ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Mar 8, 2013GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Mar 8, 2013GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 8, 2013CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 14, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 14, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 12, 2013ALIEASSIGNED TO LIE—
Feb 11, 2013ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 11, 2013REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 11, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 1, 2012RFNTREFUSAL PROCESSED BY IB—
Aug 10, 2012RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 10, 2012RFRRREFUSAL PROCESSED BY MPU—
Aug 10, 2012RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 9, 2012CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 7, 2012MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 3, 2012DOCKASSIGNED TO EXAMINER—
Aug 3, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 2, 2012REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance